New Study Finds Diabetes Drug Mounjaro Effective in Weight Loss

A groundbreaking study led by Dr. Thomas Wadden from the University of Pennsylvania has revealed that the diabetes drug Mounjaro, when combined with intensive diet and exercise, can help individuals with obesity or who are overweight lose a significant amount of weight. On average, participants in the study lost at least a quarter of their body weight, which equates to approximately 60 pounds.

In comparison, a group of individuals who also followed a strict diet and exercise regimen but received dummy shots initially experienced weight loss, but eventually regained the lost pounds. This finding emphasizes the potential power of Mounjaro as a medical treatment for obesity.

Tirzepatide, the drug’s official name, was initially approved in the United States in May 2022 as a treatment for diabetes. However, it has been used “off-label” to combat obesity with promising results. This medication targets two hormones that regulate appetite and the feeling of fullness after eating. Other drugs like Ozempic and Wegovy, which focus on one of these hormones, have also gained popularity due to their effectiveness in weight loss.

To conduct the study, approximately 800 individuals with obesity or who were overweight and had weight-related health complications were enrolled. The participants had an average weight of 241 pounds at the beginning of the trial. After three months of adhering to a strict diet and exercise plan, around 200 individuals exited the study. The remaining nearly 600 participants were randomly assigned to receive either tirzepatide or a placebo for a duration of 16 months.

The results were stunning: participants who received tirzepatide lost an additional 18.4% of their initial body weight, while those who received dummy shots experienced weight regain. Notably, around 88% of individuals taking tirzepatide lost 5% or more of their body weight, compared to only 17% of those taking the placebo. These findings demonstrate the significant impact Mounjaro can have on combating obesity.

Although the drug showcased impressive results, there were some mild to moderate side effects reported. These included nausea, diarrhea, and constipation. However, the adverse effects did not deter the participants from achieving their weight loss goals.

Encouraged by the study’s findings, pharmaceutical company Eli Lilly conducted a similar study and is anticipating comparable rates of weight loss. The company has even applied for a fast-track review from the FDA to obtain approval for the treatment of obesity with tirzepatide. A decision on the drug’s approval is expected by the end of this year.

This groundbreaking research offers hope to those struggling with obesity or being overweight. With the weight loss potential of Mounjaro, paired with a dedicated diet and exercise routine, individuals have a powerful tool to address their weight-related health complications and improve their overall well-being.